South Australian Neonatal Medication Guidelines

Furosemide (frusemide)
10mg/mL injection, 10mg/mL oral suspension
© Department for Health and Wellbeing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Dose and Indications

Diuretic

Oral

1 to 2mg/kg/dose

<table>
<thead>
<tr>
<th>Corrected Age (weeks)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;29</td>
<td>Every 24 hours</td>
</tr>
<tr>
<td>≥29</td>
<td>Every 12 to 24 hours</td>
</tr>
</tbody>
</table>

Higher doses may be used for renal failure under specialist supervision

Intravenous injection

1mg/kg/dose

<table>
<thead>
<tr>
<th>Corrected Age (weeks)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;29</td>
<td>Every 24 hours</td>
</tr>
<tr>
<td>≥29</td>
<td>Every 12 to 24 hours</td>
</tr>
</tbody>
</table>

Higher doses may be used for renal failure under specialist supervision

Continuous intravenous infusion

Initial rate 0.1 mg/kg/hour

Double the dose every 2 hours (to a maximum of 0.4mg/kg/hour) if the urine output is less than 1mL/kg/hour.

Strict monitoring of fluid input and urine output is mandatory.
Furosemide (frusemide) 10mg/mL injection, 10mg/mL oral suspension

Preparation and Administration

**Intravenous injection**

<table>
<thead>
<tr>
<th>Dose</th>
<th>1mg</th>
<th>2.5mg</th>
<th>5mg</th>
<th>7.5mg</th>
<th>10mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.25mL</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1mL</td>
</tr>
</tbody>
</table>

Administer undiluted over 15 to 30 minutes. Rate should not exceed 0.5mg/kg/minute.

Discard remaining solution.

**Continuous intravenous infusion**

Dilute 10mL of furosemide (frusemide) 10mg/mL injection with 40mL of sodium chloride 0.9% (final volume 50mL). This results in a 2mg/mL furosemide (frusemide) solution.

Do not use if discoloured. Discard solution after 24 hours.

**Oral**

<table>
<thead>
<tr>
<th>Dose</th>
<th>1mg</th>
<th>2.5mg</th>
<th>5mg</th>
<th>7.5mg</th>
<th>10mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.25mL</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1mL</td>
</tr>
</tbody>
</table>

May be administered without regards to feeds.

Lasix® (furosemide (frusemide)) 10mg/mL oral solution contains 12.7%v/v ethanol. Concerns have been expressed in relation to its safety for use in premature infants and young children, particularly when chronic therapy is required. At Women’s and Children’s Hospital, a compounded formulation is available.

The intravenous preparation may be given orally and is more cost effective when giving a single dose or expected short term use.

Furosemide (frusemide) tablets (20mg) can be used in halves and quarters (dispersed in water) if the dose can be rounded to these values.

**Compatible Fluids**

Sodium chloride 0.9%

**Adverse Effects**

**Common**

Electrolyte disturbances (hyponatraemia, hypokalaemia, hypomagnesaemia, hypocalcaemia, hypochloraemia), dehydration, hyperuricaemia, increased serum creatinine concentration

Nephrocalcinosis in preterm neonates

**Infrequent**

Dyslipidaemia, rash
Rare
Deafness (especially with rapid IV administration), acute pancreatitis, jaundice, thrombocytopenia, haemolytic anaemia, agranulocytosis, interstitial nephritis, exfoliative dermatitis, Stevens-Johnson syndrome, bullous eruptions
Supraventricular tachycardia with higher doses of furosemide(frusemide) continuous infusion

Monitoring
> Urine output
> Weight
> Serum electrolytes
> Acid/base balance
> Renal function

Practice Points
> The commercially available oral solution contains alcohol, thereby intravenous preparation is preferred to be given whilst inpatient. At discharge, parents should be counselled as to the options, which are to use the commercial preparation or to use the compounded product available from the WCHN. The risks of using the commercial preparation are unknown but considered to be very low
> Patients on long-term treatment with furosemide(frusemide) may require supplementation with oral potassium chloride to prevent hypokalaemia
> Do not use intravenous solution if discoloured yellow
> Risk of ototoxicity is increased with renal impairment, high doses, rapid IV administration and the use of other ototoxic drugs such as aminoglycosides
> Administration with other drugs with a hypotensive effect may cause an additional drop in blood pressure
> Precipitation can occur when mixed with any IV fluid such as glucose, with a pH less than 5.5. It should thereby be diluted with just 0.9% sodium chloride and always be separated by a 0.9% sodium chloride bolus
> Continuous infusion of furosemide(frusemide) compared to intermittent dosing has been reported to yield more controlled diuresis in infants post cardiac surgery

References
Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: Commissioning and Performance, SA Health
Next review due: 26/07/2026
ISBN number: 978-1-76083-359-6
CGSQ reference: NMG005
Policy history: Is this a new policy (V1)? N
Does this policy amend or update an existing policy? Y
If so, which version? V2
Does this policy replace another policy with a different title? N
If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>26/07/2021</td>
<td>V3.0</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>Formal review</td>
</tr>
<tr>
<td>07/03/2017</td>
<td>V2.0</td>
<td>SA Health Safety &amp; Quality Strategic Governance Committee</td>
<td>Formal review</td>
</tr>
<tr>
<td>11/2012</td>
<td>V1.0</td>
<td>SA Health Safety &amp; Quality Strategic Governance Committee</td>
<td>Original version</td>
</tr>
</tbody>
</table>